

# NanoSphere Develops New Product Eliminating Need to Smoke Cannabis

DENVER--(BUSINESS WIRE)--November 26, 2018--NanoSphere Health Sciences Inc. (CSE:NSHS) (OTC:NSHSF) is pleased to announce the Company has developed a new intraoral delivered cannabis product for the Canadian market, which produces similar effects to smoking cannabis, but is safer and more effective than edibles.

Regular consumers of cannabis know the effect of cannabis when smoked is very different than the effect when taken orally. The Evolve NanoGel™ uses NanoSphere's patented delivery system to transport a full spectrum of THC, other cannabinoids and terpenes through the gums and directly to the bloodstream and into cannabinoid receptors. The result for both medical and recreational consumers are vastly more effective products.

"Oils taken edibly go through the gut where THC is transformed by the liver into a more psychoactive substance called 11-hydroxy-THC (11-OH-THC)," explains Chief Science Officer Dr. Richard Clark Kaufman. "Both have psychotropic effects, but they are quite different in the way they affect the human brain, and many people do not tolerate 11-OH-THC very well."

On the other hand, Kaufman points out that smoking or vaping cannabis may have long term adverse effects on the respiratory system.

"With the NanoSphere Delivery System™ you get a very similar effect to smoking cannabis, but without risking damage to your lungs, and you don't risk an overload of 11-OH-THC as you would by taking an edible," he said.

NanoSphere, its affiliate NanoSphere Cannabis International (NCI) and partner firm **Delta 9 Cannabis Inc. (TSXV:NINE) (OTC:VRNDF) ("Delta 9")** will be applying to Health Canada for approval to have the NanoGel oil produced and sold in Canada.

"There are several issues for Canadians that this new product line can resolve," said NCI President Gary Symons. "Many landlords and condo associations are now banning the smoking of cannabis, so for many people, they literally have nowhere they can consume a legal product without risking eviction or a lawsuit."

"Just as importantly, for medical patients, NanoSphere intraoral product is designed to provide faster onset, greater bioavailability, and precise dosage," Symons added. "This product has the potential to revolutionize cannabis therapies for a variety of medical conditions."

NanoSphere is currently developing three primary types of delivery system platforms for cannabis. The first is the award-winning NanoSphere's transdermal serum which is already being produced in Colorado and California. The second is the Evolve NanoGel, an intraoral product line developed for Canada and the U.S. The third is an intranasal N2B (nose-to-brain) gel, a breakthrough product that bypasses the blood-brain barrier to deliver a much higher proportion of THC and cannabinoids directly to the brain, and, with a very fast onset time of less than 90 seconds.

NanoSphere Health Sciences holds the world's first and only patent for nanoparticle delivery of cannabinoids through the use of a new stabilized, clinically-proven natural lipid nanoparticle called a 'NanoSphere'.

## NanoSphere's Commitment to Licensing IP

NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous evaluation process. For more information about NanoSphere's licensing program, please visit: <https://www.nanospherehealth.com/licensing/>

## About NanoSphere

NanoSphere Health Sciences Inc., is a biotechnology firm specializing in the creation of the NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. NanoSphere Delivery System™ represents one of the most important developments for advancing the non-invasive and user-friendly delivery of biological agents in over 25 years. For more information on NanoSphere, please visit <http://www.nanospherehealth.com>.

## About Evolve Formulas

Evolve Formulas is the provider of the world's first and only scientifically proven nanoparticle delivery system in cannabis. Evolve's pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. NanoSerum™ immediately penetrates the skin to deliver direct-focused results and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing. Evolve Formula products leverage NanoSphere Health Sciences™ patented NanoSphere Delivery System™. The NanoSphere Delivery System™ is a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on Evolve Formulas, visit <https://www.evolveformulas.com/>. Follow us on Facebook, Instagram and Twitter.

*The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.*

## Forward Looking Statement Caution

*This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Without limitation, these include assumptions, risks and uncertainties inherent in completing sub-licensing arrangements in the United States, Canada and abroad, product demand, production, competition and government regulation of the Cannabis industry, any and all of which may have an adverse effect on the Company's expansion plans, sales, revenues and its financial results and condition. In this release the Company's intention to produce and sell the Evolve NanoGel product depends upon Health Canada approving the product for distribution in Canada, and there is no guarantee this will happen. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.*

### CONTACT:

#### **On behalf of the Board**

David Sutton, President and COO

720.520.4283

[dsutton@nanospherehealth.com](mailto:dsutton@nanospherehealth.com)

Victor Goncalves, Executive Vice President

**Mobile:** 204-997-5517

**E-mail:** [vgoncalves@nanospherehealth.com](mailto:vgoncalves@nanospherehealth.com)